Additionally, Khalife et al. reported that MLN4924 drug (Pevonedistat), decreasing NF-κB activation, downregulated oncogenic miR-155 levels in FLT3-ITD+ AML cell lines and reduced leukemic phenotypes, in both in vitro and in vivo models [177]. Here, FLT3 is linked to acute myeloid leukemia.